

Plazomicin

Essential medicine status

General description

Plazomicin is a next-generation aminoglycoside ("neoglycoside") used in the treatment of multi-drug resistant infections caused by carbapenem resistant Enterobacteriaceae, carbapenem-resistant *Pseudomonas aeruginosa* and carbapenem-resistant *Acinetobacter baumannii*.

INN

Plazomicin

ATC codes

[J01GB14](#)

Medicine type

Chemical agent

Antibiotic groups

[RESERVE](#)

EML status history

First added in 2019 ([TRS 1021](#)) for [Carbapenem resistant Enterobacterales](#)

Added in 2019 ([TRS 1021](#)) for [Carbapenem-resistant Pseudomonas aeruginosa](#)

Added in 2019 ([TRS 1021](#)) for [Carbapenem resistant Acinetobacter baumannii](#)

Wikipedia

[Plazomicin](#)

DrugBank

[Plazomicin](#)

Recommendations

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Enterobacterales](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Acinetobacter baumannii](#)